DAYLI Partners

Medipixel, Inc., founded in 2017 and based in Seoul, South Korea, specializes in developing artificial intelligence-based diagnostic software and semi-autonomous surgical tools for lung cancer and cardiac disease interventions. The company employs a team of experts in computer vision, deep learning, and reinforcement learning, collaborating with leading healthcare institutions to enhance diagnostic and surgical processes. Medipixel offers several innovative solutions, including an AI-based diagnosis tool that assists doctors in identifying lesions during coronary angiography, a guide and planning solution that visualizes hidden coronary artery segments to facilitate guidewire manipulation, and an automated navigation engine that optimizes robotic control for surgical procedures. By integrating advanced AI technologies, Medipixel aims to improve the quality of medical care and patient outcomes in the field of surgery.

CURAUM Inc. specializes in the development and sale of oral care and sleep-related health care products in South Korea. Founded in 2017 and headquartered in Yuseong, with additional offices in Seoul, Incheon, and Newport Beach, California, the company offers innovative devices designed to improve oral hygiene and manage sleep disorders. Its product lineup includes the Clium Cleaner, which sterilizes and stores dental devices, the Clium S-Guard, an omnidirectional device aimed at treating obstructive sleep apnea and snoring, and the Clium System, a home health care solution that personalizes management of chronic sleep issues. CURAUM also focuses on collecting and analyzing consumer health data to monitor hygiene status and predict symptoms of potential diseases, thereby promoting preventive health habits.

Y-Biologics Inc. is a biotechnology company based in Daejeon, South Korea, specializing in the discovery and development of novel antibody therapeutics, particularly in the field of immuno-oncology. Established in 2007, the company has developed a unique bispecific antibody platform technology known as AliCE, which retains the structure of the parental antibody to ensure high binding affinity to cancer antigens. Additionally, Y-Biologics has created the Y-max ABL library, which comprises a diverse range of antibodies. The company also offers contract research services, further contributing to its position in the antibody drug market. Through its innovative technologies and research efforts, Y-Biologics aims to advance its portfolio of antibody drugs and strengthen its role in the global immuno-chemotherapeutic landscape.

Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on creating anti-cancer drugs through its innovative proteolysis targeting chimera platform technology. This approach employs inhibitor technology to degrade specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with targeted diseases, Ubix Therapeutics seeks to provide effective and life-saving treatments for patients, thereby supporting medical professionals in their efforts to combat cancer.

Tomocube Inc. specializes in the design and manufacture of 3D optical microscopes, particularly the HT-1 and HT-2 models, which offer holotomographic imaging and 3D fluorescence capabilities. Founded in 2015 and headquartered in Daejeon, South Korea, the company aims to enhance biological and medical research through innovative optical solutions. Unlike traditional optical microscopes that provide only 2D views, Tomocube's products enable researchers to obtain real-time, dynamic 3D images of living cells without the need for extensive sample preparation. This technology is particularly beneficial for studying various biological samples, including red blood cells, sperm cells, CAR-T cells, and more. By utilizing deep learning-based image recognition, Tomocube's microscopes allow for a better understanding of cellular dynamics, ultimately aiding in the diagnosis and treatment of human diseases.

GI Innovation is a South Korean bio-venture company dedicated to the research and development of innovative biologics aimed at treating immuno-oncology and inflammation/immunology diseases. The company employs its proprietary GI-SMART platform technology, which optimizes the development of multi-targeting fusion protein therapeutics, ensuring high quality and productivity. Through its structured translational research approach, GI Innovation focuses on creating new protein-based drugs, particularly in the fields of immuno-oncology and allergy-related conditions, with the goal of improving patient outcomes worldwide.

Master Meditech Inc., established in 2019 and located in Seoul, South Korea, focuses on the development of new pharmaceuticals through the identification of protein structures and the application of medicinal chemistry. The company aims to innovate drug discovery by leveraging advanced scientific techniques to create effective therapeutic solutions.

CURAUM Inc. specializes in the development and sale of oral care and sleep-related health care products in South Korea. Founded in 2017 and headquartered in Yuseong, with additional offices in Seoul, Incheon, and Newport Beach, California, the company offers innovative devices designed to improve oral hygiene and manage sleep disorders. Its product lineup includes the Clium Cleaner, which sterilizes and stores dental devices, the Clium S-Guard, an omnidirectional device aimed at treating obstructive sleep apnea and snoring, and the Clium System, a home health care solution that personalizes management of chronic sleep issues. CURAUM also focuses on collecting and analyzing consumer health data to monitor hygiene status and predict symptoms of potential diseases, thereby promoting preventive health habits.

Sugentech Incorporated is an in-vitro diagnostic company based in Daejeon, South Korea, specializing in personal point-of-care testing products and personalized diagnosis solutions. Founded in 2011, the company focuses on developing innovative healthcare technologies by integrating biotechnology, information technology, and nanotechnology. Sugentech's product offerings include laboratory tests such as immunoblot processors and molecular diagnostics systems, as well as self-diagnostic home testing kits. Their portfolio features tests for various analytes, including C-reactive protein, procalcitonin, and troponin I, along with personal care tests like digital ovulation and pregnancy tests. Formerly known as Accugen Healthcare, Sugentech changed its name in 2013 to reflect its commitment to pioneering advancements in health diagnostics.

CSK Inc. is a manufacturer specializing in products for the semiconductor and LCD industries, with a presence in Asia, America, and other international markets. Founded in 1997 and based in Yongin, South Korea, the company provides exhaust management systems, including plasma and wet scrubbers that effectively purify harmful gases produced during semiconductor manufacturing. Additionally, CSK offers precursor delivery systems aimed at waste gas abatement. As of August 2016, CSK operates as a subsidiary of Atlas Copco AB, serving key sectors such as semiconductor, display, solar, and LED markets in South Korea.

Medipixel, Inc., founded in 2017 and based in Seoul, South Korea, specializes in developing artificial intelligence-based diagnostic software and semi-autonomous surgical tools for lung cancer and cardiac disease interventions. The company employs a team of experts in computer vision, deep learning, and reinforcement learning, collaborating with leading healthcare institutions to enhance diagnostic and surgical processes. Medipixel offers several innovative solutions, including an AI-based diagnosis tool that assists doctors in identifying lesions during coronary angiography, a guide and planning solution that visualizes hidden coronary artery segments to facilitate guidewire manipulation, and an automated navigation engine that optimizes robotic control for surgical procedures. By integrating advanced AI technologies, Medipixel aims to improve the quality of medical care and patient outcomes in the field of surgery.

MDimune Inc. is a therapeutics company based in Seoul, South Korea, established in 2015. It specializes in developing innovative drug delivery systems, particularly utilizing vesicles derived from immune and stem cells. The company focuses on creating targeted delivery methods to enhance the efficacy of treatments for conditions such as cancer, osteoarthritis, chronic obstructive pulmonary disease, and neurodegenerative diseases. MDimune's BioDrone platform enables the manufacture and supply of these vesicles, allowing biotechnology and pharmaceutical firms to develop novel therapeutics aimed at delivering drugs precisely to target tissues. This approach facilitates the provision of advanced anticancer therapies to patients, aligning with the company's mission to improve treatment outcomes through smart drug delivery solutions.

HUINNO, Inc., founded in 2014 and headquartered in Boston, Massachusetts, develops healthcare devices that monitor vital health data, including blood pressure, heart rate, electrocardiogram (ECG), and blood oxygen saturation levels (SpO2). The company leverages proprietary technologies in wearable devices and artificial intelligence to provide healthcare providers with an effective remote patient monitoring solution aimed at improving the management of chronic cardiac diseases. HUINNO's clinically-tested platform delivers real-time measurements with clinical-grade accuracy and offers an application and cloud-based ecosystem for longitudinal analysis of health trends, medication compliance, and lifestyle habits. This comprehensive approach not only enhances patient care but also aids healthcare professionals in making informed medical decisions while treating conditions such as arrhythmia and hypertension. With additional offices in New York and Seoul, HUINNO is committed to transforming the way clinicians and patients manage chronic health issues.

Tomocube Inc. specializes in the design and manufacture of 3D optical microscopes, particularly the HT-1 and HT-2 models, which offer holotomographic imaging and 3D fluorescence capabilities. Founded in 2015 and headquartered in Daejeon, South Korea, the company aims to enhance biological and medical research through innovative optical solutions. Unlike traditional optical microscopes that provide only 2D views, Tomocube's products enable researchers to obtain real-time, dynamic 3D images of living cells without the need for extensive sample preparation. This technology is particularly beneficial for studying various biological samples, including red blood cells, sperm cells, CAR-T cells, and more. By utilizing deep learning-based image recognition, Tomocube's microscopes allow for a better understanding of cellular dynamics, ultimately aiding in the diagnosis and treatment of human diseases.

SCM Lifescience, founded in 2014, focuses on the research and development of innovative treatment options for challenging diseases, aiming to improve patient outcomes and contribute to public health. The company specializes in proprietary stem cell isolation and production technologies, which form the basis of its products, including medicines and hair care solutions. Based in South Korea, SCM Lifescience is committed to advancing medical science through its development of stem cell products and therapies, providing hope for patients with difficult-to-treat conditions.

Y-Biologics Inc. is a biotechnology company based in Daejeon, South Korea, specializing in the discovery and development of novel antibody therapeutics, particularly in the field of immuno-oncology. Established in 2007, the company has developed a unique bispecific antibody platform technology known as AliCE, which retains the structure of the parental antibody to ensure high binding affinity to cancer antigens. Additionally, Y-Biologics has created the Y-max ABL library, which comprises a diverse range of antibodies. The company also offers contract research services, further contributing to its position in the antibody drug market. Through its innovative technologies and research efforts, Y-Biologics aims to advance its portfolio of antibody drugs and strengthen its role in the global immuno-chemotherapeutic landscape.

Ensol Biosciences Inc. is a biopharmaceutical company based in Daejeon, South Korea, focused on developing innovative therapies for diseases that currently lack effective treatments, including degenerative disc disease, osteoarthritis, cancer, type 1 diabetes, and Alzheimer's dementia. The company's drug pipeline features several candidates, such as Peniel 2000, which is undergoing Phase II clinical trials for degenerative disc disease, and Engedi 1000, currently in Phase I trials for osteoarthritis. Ensol also develops oncology drugs like Charis 1000 for triple negative breast cancer and Moriah 1000 for Alzheimer’s disease. In addition to its drug development efforts, the company offers contract drug development services and operates the Knowledge-based In Silico Drug Discovery (KISDD 2.0) platform for screening potential drug candidates. Ensol Biosciences was founded in 2001 and rebranded from Ensoltek Co., Ltd. in 2015.

3D MediVision, Inc. specializes in developing and manufacturing 3D visualization and live-casting systems specifically designed for surgical applications. Established in 2011 and based in Seoul, South Korea, the company offers a range of products including 3D/2D cameras, recorders, monitors, and ultrasound systems. Its technology enables surgeons to capture and display surgical procedures in high-definition 3D images, which can be streamed or recorded for educational purposes. Additionally, 3D MediVision provides SURGFLIX, a surgical content sharing platform for professionals, and VeterFlix, tailored for veterinary training. The company's products are distributed through authorized partners in various countries, including India, Spain, Mexico, and China, facilitating enhanced collaboration and knowledge sharing among surgical teams.

42Maru, Inc. is a South Korean company founded in 2015 that specializes in developing advanced search engine technology for artificial intelligence applications. The company focuses on creating a deep learning-based question-answering (QA) system that accurately interprets user intent to provide unique, correct answers. This technology is applicable across various platforms, including smart speakers, connected cars, and chatbots. 42Maru's core competencies include high accuracy, rapid response times, and a self-expanding knowledge base, distinguishing it from traditional rule-based and inference-based systems. The company aims to penetrate the consumer market through strategic B2B2C alliances, targeting sectors such as home IoT, personal assistants, and smart toys. With a strong team led by a CEO with over 20 years of experience in the search engine industry, 42Maru is positioned for global expansion and multi-language support, capitalizing on the growing demand for AI-driven search solutions.